The Translational Genomics Research Institute (TGen) has announced a $3 million grant from the Ben & Catherine Ivy Foundation in Scottsdale, Arizona, in support of a collaboration with Nemucore Medical Innovations and the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center to develop personalized therapies for the treatment of brain tumors.
The grant will support the efforts of the three research partners to optimize targeted therapies delivered by nanotechnology systems to address glioblastoma, the most common and aggressive form of malignant brain tumor. A primary goal of the project is to align the partners' respective findings toward the goal of creating new medications that can bridge the body's blood-brain barrier, which in the past has hampered the successful implementation of intravenous brain-cancer drugs.
Based on the findings, research team members will work with Blue Ocean Biomanufacturing to develop methods to economically manufacture personalized therapies for the treatment of glioblastoma.
"We are excited about this innovative approach to research, especially the collaboration between two major Arizona institutions: TGen and Barrow," said Ivy Foundation founder and president Catherine Ivy. "Knowing there is a tangible way to develop therapies specific to the needs of patients will enhance the care and treatment of every brain tumor patient — and that is priceless."